Why the study?
Findings from BRIGHT-4 showing reduced mortality and bleeding with bivalirudin plus a post-PCI high-dose infusion versus heparin alone in STEMI required external validation.
Does bivalirudin reduce all-cause mortality compared to heparin in STEMI patients undergoing primary PCI?
Does bivalirudin reduce all-cause mortality compared to heparin in STEMI patients undergoing primary PCI?
In STEMI patients undergoing primary PCI, bivalirudin with a high-dose post-PCI infusion reduces cardiac mortality and major bleeding without increasing ischemic events compared to heparin.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“We have spent the better part of the last 4 years collecting, cleaning, and analyzing the data. There was less thrombocytopenia, there was less need for blood transfusions, there were substantial benefits in the STEMI patients with bivalirudin, and now that it's generic the cost is not very different [from heparin], so I don't see why it wouldn't be used.”
“Bivalirudin should be considered the preferred regimen in the cath lab for patients with STEMI undergoing primary PCI due to reduced mortality and overall adverse outcomes.”
“The reason why I find it not a practice-changing meta-analysis is because it continues to be confounded by the same principal problem that has dogged this field from very early on, and that is that you cannot make a correct comparison of the relative safety and efficacy of heparin and bivalirudin if there is disproportionate GPI use in one arm.”
Warrants bivalirudin preference over heparin for primary PCI in STEMI; confirms mortality benefit in contemporary RCT meta-analysis.
BACKGROUND In the BRIGHT-4 (Bivalirudin With Prolonged Full-Dose Infusion During Primary PCI Versus Heparin Trial-4), anticoagulation with bivalirudin plus a 2- to 4-hour high-dose infusion after percutaneous coronary intervention (PCI) reduced all-cause mortality and bleeding without increasing reinfarction or stent thrombosis compared with heparin alone in patients with ST-segment elevation myocardial infarction (STEMI). These findings require external validation. OBJECTIVES This study sought to determine outcomes of bivalirudin vs heparin anticoagulation during PCI in STEMI. METHODS We performed an individual-patient-data meta-analysis of all large randomized trials of bivalirudin vs heparin in STEMI patients undergoing primary PCI performed before BRIGHT-4. The primary endpoint was all-cause mortality. RESULTS Six trials randomizing 15,254 patients were included. Pooled across all regimens of bivalirudin and glycoprotein IIb/IIIa inhibitor (GPI) use, bivalirudin reduced 30-day all-cause mortality (2.5% vs 2.9%; adjusted OR: 0.78; 95% CI: 0.62-0.99), cardiac mortality (adjusted OR: 0.69; 95% CI: 0.54-0.88), and major bleeding (adjusted OR: 0.53; 95% CI: 0.44-0.64) but increased reinfarction (adjusted OR: 1.30; 95% CI: 1.02-1.65) and stent thrombosis (adjusted OR: 1.43; 95% CI: 1.05-1.93) compared with heparin. In 4 trials in which 6,244 patients were randomized to bivalirudin plus a high-dose post-PCI infusion vs heparin without planned GPI use (the BRIGHT-4 regimens), 30-day all-cause mortality occurred in 1.8% vs 2.9% of patients, respectively (adjusted OR: 0.74; 95% CI: 0.48-1.12), and bivalirudin reduced cardiac mortality (adjusted OR: 0.62; 95% CI: 0.39-0.97) and major bleeding (adjusted OR: 0.49; 95% CI: 0.35-0.70), with similar rates of reinfarction (adjusted OR: 0.89; 95% CI: 0.58-1.38) and stent thrombosis (adjusted OR: 0.80; 95% CI: 0.41-1.57). CONCLUSIONS In STEMI patients undergoing primary PCI, bivalirudin with a 2- to 4-hour post-PCI high-dose infusion reduced cardiac mortality and major bleeding without an increase in ischemic events compared with heparin monotherapy with provisional GPI use, confirming the BRIGHT-4 results.
No takes yet. Share an insight, caveat, or question.
Stone et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: